Answers are grounded in this paper and cite their sources.
Umbrella review and meta-analysis demonstrates increased remission rates in patients with depression, indicating that genetic profiling improves antidepressant selection.
Aim: To determine the efficacy and safety of pharmacogenomics (PGx)-guided antidepressant prescribing in patients with depression through an umbrella review and updated meta-analysis. Methods: A comprehensive systematic search was conducted on PsycINFO, PubMed, Embase and the Cochrane databases. The pooled effect sizes of randomized controlled trials (RCTs) were expressed as mean differences for continuous data and risk ratios for noncontinuous data. Results: Patients who received PGx-guided medications were 41% to 78% more likely to achieve remission and 20% to 49% more likely to respond to antidepressants than patients receiving treatment-as-usual (TAU). Conclusion: PGx-guided antidepressant prescribing improves the treatment of depression. However, the significance and magnitude of the benefit varies widely between studies and different PGx testing panels. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022321324.
No takes yet. Share an insight, caveat, or question.
Tesfamicael et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: